This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
New Strong Sell Stocks for September 8th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Adverum (ADVM) Surges: Stock Moves 6.2% Higher
by Zacks Equity Research
Adverum (ADVM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -20.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Timing the Market, Is it Possible? - June 26, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
The Market Timing Secrets No One Talks About - June 05, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Adverum Biotechnologies (ADVM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -14.81% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ADVM) Outperforming Other Medical Stocks This Year?
Simple Market Timing Strategies That Work - May 12, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Is Adverum Biotechnologies (ADVM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ADVM) Outperforming Other Medical Stocks This Year?
Here's Why Momentum Investors Will Love Adverum Biotechnologies (ADVM)
by Zacks Equity Research
Does Adverum Biotechnologies (ADVM) have what it takes to be a top stock pick for momentum investors? Let's find out.
All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy
by Zacks Equity Research
Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Adverum (ADVM): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Adverum (ADVM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
What Makes Adverum Biotechnologies (ADVM) a New Buy Stock
by Zacks Equity Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adverum Biotechnologies (ADVM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 6.45% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Adverum (ADVM)
by Zacks Equity Research
Adverum (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Offing for Ring Energy (REI) Q4 Earnings?
by Zacks Equity Research
While a substantial ramp-up in output is expected to have driven Ring Energy's (REI) fourth-quarter 2019 earnings, lower commodity prices might dampen its overall results.
The Truth About Market Timing - March 06, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Earnings Preview: Adverum Biotechnologies (ADVM) Q4 Earnings Expected to Decline
by Zacks Equity Research
Adverum Biotechnologies (ADVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Keys to Successfully Timing the Markets - February 14, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
The Market Timing Secrets No One Talks About - January 27, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Simple Market Timing Strategies That Work - January 07, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Timing the Market, Is it Possible? - November 25, 2019
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 7.41% and -47.92%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
When Does Market Timing Actually Work? - November 04, 2019
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?